Virtual Library
Start Your Search
E. Prado
Author of
-
+
P1.01 - Poster Session with Presenters Present (ID 453)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Epidemiology/Tobacco Control and Cessation/Prevention
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.01-033 - EGFR Mutation and ALK: Are Patients Being Adequately Tested in Brazil? (ID 5818)
14:30 - 14:30 | Author(s): E. Prado
- Abstract
Background:
Lung cancer is one of the most common malignancies in the world. In Brazil, it is estimated that 28,200 new cases will be diagnosed in 2016. This cancer affects more men and is usually caused by tobacco exposure. The most common histology is adenocarcinoma and many of these patients have driver mutations which help guide therapeutic choice. The aim of this study was to delineate the epidemiological profile of patients with NSCLC in Brazil and to evaluate the prevalence of testing for ALK translocations and EGFR mutations in patients in the public and private settings in Brazil.
Methods:
Observational, descriptive, retrospective, multicenter study involving 230 public and private institutions in Brazil. We obtained data from a commercial database with 1642 Non Small Cell Lung Cancer (NSCLC) patients treated in the country between January and December 2015. Variables analyzed: age, sex, smoking, presence of EGFR and ALK mutation.
Results:
Out of 1642 patients, 814 were treated in the public service (49.57%) and 828 in private services (50.42%). Most patients were men (58.28% vs. 41.71% female). The mean age at diagnosis was 61.8 years (median 62 years), 32.58% were former smokers, 31.12% current smokers, 19.48% never smoked and data were not available for 16.8% of subjects. Most patients had metastatic disease at diagnosis (65.04%), 23.20% had stage III, 9.31% stage II and 2.43% stage I. 68.57% had adenocarcinoma, 27.52% squamous cell cancers, 1.4% large cell and 2.67% had other histological types. Among the 534 patients with non-squamous histology treated in public settings, 244 patients were tested for EGFR (46,69%) and only and only 36 were tested for ALK (6,74%).In private services, of 656 patients with non-squamous subtypes, 454 were tested for EGFR (69,2%) and 77 for ALK (11,73%).
Conclusion:
Overall, testing for EGFR mutations was below ideal, especially in the public setting. More worryingly, and likely due to the lack of availability of crizotinib in Brazil until 2016, very few patients were tested for ALK translocations in 2015. Much work needs to be done in education and advocacy to improve testing patterns in the country.
